Celipress^® is the preparation of celiprolol hydrochloride. It is a beta1-selective (cardioselective), beta-adrenoreceptor blocking agent which possesses mild beta2 agonist activity and weak alpha2 blocking activity, but does not exhibit quinidine-like membrane stabilizing properties. These and other receptor modulating effects may account for its absence of cardiodepressant effect, lack of adverse effects on serum lipids, decreases in peripheral vascular resistance as well as a reduced risk of adverse bronchopulmonary effects compared with other beta-adrenoreceptor blocking agents.

Celipress^® is indicated for the treatment hypertension and effort-induced angina pectoris.

Celipress^® should be taken at least one hour before or two hours after meals.
Hypertension: The recommended initial dose is 200 mg once daily. The effect will be fully established after one to two weeks. The dose may be increased to 400 mg once daily, if necessary, at 2 to 4 week intervals.
Angina Pectoris: It is indicated for the long-term management of patients with angina pectoris. The usual dose is 200 mg once daily. Dosage may be increased to 400 or 600 mg once daily after 2 to 4 week intervals until optimum clinical response obtained. If treatment is to discontinue, reduce the dosage gradually over a period of one to two weeks.

All beta blockers are contraindicated in bronchial asthma or other obstructive lung disorders, uncontrolled heart failure, cardiogenic shock, sick-sinus syndrome, grade 2 and 3 A-V block, infranodal A-V block and severe bradycardia and also avoid in severe renal impairment.
 

Celipress^® is not teratogenic in experimental animals but is embryotoxic in rabbits and rats at 54 to 60 times the highest recommended human oral dose. It crosses the placenta in animals and it is not known to what extent it crosses the placenta in humans. It should not be given in pregnancy unless its use is considered to be essential. The extent to which celiprolol is excreted in breast milk has not been established and breast-feeding should not be continued by mothers receiving this product.
 

Pregnancy and breast-feeding ; avoid abrupt withdrawal especially in angina; first-degree AV block; reduce oral dose of celiprolol in liver disease; renal impairment ; diabetes; history of obstructive airways disease. Celiprolol therapy must be reported to the anaesthetist prior to general anaesthesia.
 

Verapamil and celiprolol both slow A-V conduction and depress myocardial contractility through different mechanisms. Therefore, clinical signs and electrocardiogram should be carefully monitored during the treatment with this combination particularly when initiating therapy. The bioavailability of celiprolol has been shown to be reduced by the concomitant administration of chlorthalidone, hydrochlorothiazide or theophylline. While no effect on the efficacy of celiprolol has been demonstrated, patient response should be monitored after dosage adjustments involving these medications.
 

Adverse experiences have usually been transient and mild. Among those most frequently observed were headache, dizziness, fatigue, abdominal discomfort, weakness, rash, bradycardia, oedema, palpitation amd muscle cramps ; depression and pneumonitis reported rarely.
 

Store in a cool and dry place, away from light. Keep out of reach of children.
 

Celipress^® 200 mg tablet: Box containing 2 strips of 10 tablets each. Each tablet contains celiprolol hydrochloride BP equivalent to celiprolol 200 mg.
Celipress^® 400 mg tablet: Box containing 1 strip of 10 tablets each. Each tablet contains celiprolol hydrochloride BP equivalent to celiprolol 400 mg.
 


Manufactured by:
ESKAYEF BANGLADESH LTD
DHAKA, BANGLADESH
® REGD.TRADEMARK